ArticleHuman cell2025
Bone marrow mesenchymal stem cell-derived exosomal METTL14 promotes the osteogenic differentiation of MC3T3-E1 cells by regulating BMP2 in bone fracture recovery.
Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Chondrocytes in fracture healing: A review of chondrocyte journey.Chinese medical journal · 2026Review
- Recent advances in the use of stem cell-derived exosomes for joint regeneration.Molecular biology reports · 2026Review
- Identification of active metabolites fromFrontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone fracture healing is a complex physiologic process that aims at restoring the damaged bone to its pre-injury state and cellular composition. Exosomes secreted by bone marrow mesenchymal stem cells (BMSCs) are emerging as a promising strategy to promote bone regeneration due to exosomal bioactive cargos. Furthermore, N6-Methyladenosine (m6A) methylation affects osteoblastic differentiation and bone remodeling. This study is designed to clarify the role and mechanism of BMSC-derived exosomal Methyltransferase-like 14 (METTL14) in osteogenesis. METTL14 and bone morphogenetic protein 2 (BMP2) levels were detected by RT-qPCR. METTL14, exosome-specific markers, BMP2, and IGF2BP1 protein levels were determined using Western blot. Cell viability, proliferation, and apoptosis were examined using MTT, EdU, and flow cytometry. The degree of osteogenic differentiation was verified by the Alizarin Red S staining assay and ALP activity assay. The interaction between METTL14 and BMP2 was analyzed using methylated RNA immunoprecipitation (MeRIP)-qPCR and RIP assays. METTL14 and BMP2 levels were decreased in delayed fracture healing (DFH), a common complication after fracture surgery. METTL14 upregulation expedited MC3T3-E1 cell viability, proliferation, and repressed apoptosis. METTL14 promotes osteogenic differentiation of MC3T3-E1 cells by enhancing ALP activity and mineralized formation. After co-culturing BMSC-derived exosomes and MC3T3-E1 cells, BMSC-derived exosomal METTL14 expedited the osteoblast activity. Mechanistically, METTL14 stabilized BMP2 mRNA through the m6A-IGF2BP1-dependent mechanism. These findings indicated that BMSC-derived exosomes encapsulate METTL14 and transport it into MC3T3-E1 cells, and the transported METTL14 could accelerate the osteogenesis by regulating the stability of BMP2 mRNA, which provided a potentially effective therapeutic strategy for bone regeneration.
Indexed as
Identifiers
40794239What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.